Clinical Research Directory
Browse clinical research sites, groups, and studies.
An Exploratory Study of Cluster of Differentiation 38 (CD38) Monoclonal Antibody Combined Corticosteroid in Acquired Hemophilia A
Sponsor: Institute of Hematology & Blood Diseases Hospital, China
Summary
To evaluate the time of response, sustained remission rate and relapse rate of CD38 monoclonal antibody (Daratumumab) combined corticosteroid in the treatment of AHA. To evaluate the safety of CD38 monoclonal antibody in the treatment of AHA.
Official title: A Multicenter, Single-arm Exploratory Study of CD38 (Daratumumab) Monoclonal Antibody (Daratumumab) Combined Corticosteroid in the Treatment of Acquired Hemophilia A (AHA)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
25
Start Date
2023-05-22
Completion Date
2027-10-31
Last Updated
2025-08-05
Healthy Volunteers
No
Conditions
Interventions
Daratumumab and corticosteroid treatment
Daratumumab and corticosteroid treatment
Locations (1)
Chinese Academy of Medical Science and Blood Disease Hospital
Tianjin, China